Insilico Medicine Received IND Approval and Orphan Drug Designation from FDA for ISM6331, an AI-designed TEAD Inhibitor Targeting Solid Tumors and Mesothelioma (IMAGE)

InSilico Medicine

Insilico Medicine Received IND Approval and Orphan Drug Designation from FDA for ISM6331, an AI-designed TEAD Inhibitor Targeting Solid Tumors and Mesothelioma

Caption

The development of ISM6331 was significantly accelerated by AI, where Chemistry42, Insilico’s generative chemistry engine, yielded 3 promising hit series in the first round of compound generation.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.